A new study into the effectiveness of NEO212, a conjugate formulation of Temozolomide (TMZ) and Perillyl Alcohol (POH) designed for intranasal delivery, to enhance the ability of (TMZ) to slow or stop the formation of Glioblastoma Tumors suggests additional benefits over TMZ treatment alone. For those with Glioblastoma (GB) brain cancer, the survival prognosis is […]